Shire’s Hunter Syndrome Drug Disappoints in Late-Stage Study

Shire announced that its experimental treatment for children with Hunter syndrome and cognitive impairment, SHP609, failed to meet the main and secondary goals of a late-stage clinical trial.

SHP609 is being tested in combination with Elaprase, Shire’s existing drug that treats Hunter syndrome but not cognitive impairment.

According to Shire, the study’s primary endpoint evaluated the difference in cognition between the SHP609-treated and control groups, as measured by change from baseline in General Conceptual Ability (GCA) scores in children with Hunter syndrome after 12 months of treatment. The key secondary endpoint evaluated the difference between the SHP609-treated and control groups as measured by the change from baseline in Adaptive Behavior Composite (ABC) score.

Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive licensing rights for the global development and commercialization of two cancer drugs.

A mix of feature articles and current new stories that are critical to staying up-to-date on the industry, delivered to your inbox. Choose from an assortment of different topics and frequencies. Subscribe Today.